TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Area under the concentration-time curve from time zero to last time of quantifiable concentration (AUC (0-t)) of total drug-related material (radiocarbon) in blood and plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Minimum observed concentration (Cmax) of total drug-related material (radiocarbon) in blood and plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of severe hypotension
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative duration of hypotension
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CIED related infection
Endpoint domain: Adverse events/effects
Primary endpoint: HbA1c (mean value in %)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: high sensitive C-Reactive Protein - hs-CRP (mean value in mg/L)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: proportion of patients with modified Rankin Score 0 to 2
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Number and Percentage of Lesions That Were Stained Positive
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity and Specificity (Percentage of True Positives and True Negatives)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Abaloparatide Maximum Plasma Concentration (Cmax) on Day 29
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Abaloparatide Area Under the Plasma Concentration-Time Curve (AUC0-t) on Day 29
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Antibody concentration/response to all vaccine antigens
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of patients approached who consent to use of pharmacogenomic algorithm
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Amount of time from ordering test to receipt of results
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Proportion of time that the physician prescribed a medication that was recommended by the algorithm
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Hepatic Triglyceride (%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: PNIF (peak nasal inspiratory flow)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VAS (visual analogue score) for nasal obstruction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VAS (visual analogue score) for rhinorrhea
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients who develop post ERCP pancreatitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Schirmer's test 1 result
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ocular surface Oxford scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ocular surface disease index scale (OSDI)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Fluorescein staining of eye
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Retention of SARS-CoV-2 IgG antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Median Visual Analogue Score Measuring Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: brain parenchymal relaxation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in management of pain related to spinal cord injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Paracetamolemia dosage after intravenous route
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Paracetamolemia dosage after subcutaneous route
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Breastfeeding Self efficacy change
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Postpartum depression change
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Percentage of patients achieving FPG <100mg/dL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Time until changes in antiparkinsonian therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in condition of the shoulder
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Number of Subjects Progressing
Endpoint domain: Mortality/survival
Primary endpoint: post-discharge medication adherence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Changes in ALT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Normalization of liver enzymes, immunoglobulins, and bilirubin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: No SAEes greater than grade 3
Endpoint domain: Adverse events/effects
Primary endpoint: Residual dorsal angulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete clinicohematologic response rate (CHR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Reaching failure criterion (FiO2= 65% while receiving nasal CPAP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Percentage change in health related quality of life (HRQOL) total score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: CTA examination results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Performance of Non-Invasive Comprehensive Metabolic Panel
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Perceived level of fatigue
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Perceived self efficacy in coping with fatigue
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Duration of successful rechallenge
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Global cognitive ability
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in the Number of Wet Nights
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline blood glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change from baseline blood cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Brain edema
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Percentage of tacrolimus levels in range after transplantation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Emergent Serious Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Change of Apnea-Hypopnea Index (AHI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change of Snore Index (SI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Cocaine-Induced 'High'
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: in-stent binary restenosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Recovery of the vocal fold mobility
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Voice recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Operative Mortality
Endpoint domain: Mortality/survival
Primary endpoint: Change from baseline in mSBP and mDBP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in functional sympatholysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Change in vascular alpha 1 adrenergic responsiveness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Change in exaggerated pressor responses during exercise
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Endometrial thickness ≥ 7 mm
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Maximum plasma concentration (Cmax) of iloperidone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration-time Curve (AUCinf) of iloperidone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: accuracy level of emotional facial expressions recognition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reaction time of emotional facial expressions recognition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Asthma Control Test Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Troponin T area under the curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Return to full physical activity
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Hospital Anxiety & Depression Scale (HADS) Score - Depression Sub-score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Positive hepatitis B surface antigen test result
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Expulsion rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of infection of the sternal surgical wound
Endpoint domain: Adverse events/effects
Primary endpoint: change in deep brain blood flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Clinically Meaningful Change in Lamotrigine Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Clinically Meaningful Change in Levetiracetam Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Clinically Meaningful Change in Oxcarbazepine Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes in heart sounds measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Glutamate scavengers (Glu-sca) levels in serum
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Glutamate (Glu) levels in serum
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in reactive hyperemia index (RHI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: normalised aortic diameter at the level of the sinus of valsalva
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: SVR 24 (Sustained Virologic Response at 24 weeks)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: safety of the fentanyl HCl 40 mcg system
Endpoint domain: Adverse events/effects
Primary endpoint: Total number of positive findings in blood cultures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Performance of Masimo SpHb sensor
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of inhibition of TxB2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Mortality of Participants
Endpoint domain: Mortality/survival
Primary endpoint: Number of additional lymph nodes obtained
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Local anesthetic consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pulsatility index of maternal middle cerebral artery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Resistive index of maternal middle cerebral artery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percent Change in MBT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean absolute error (MAE) in refractive error
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete regression of anal intraepithelial neoplasia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Changing of scar on the donor site
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change From Baseline in Average Systolic Blood Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change From Baseline of Total Cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Total duration of respiratory support
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Full mouth plaque score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intracranial elastance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: crevicular fluid VEGF levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: crevicular fluid PDGF-BB levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional and structural connectivity of brain regions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Biomarkers of brain alterations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Rectovaginal fistula repair success
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Reduction in number of cigarettes smoked
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With On-treatment Serious Adverse Events (SAEs) and Non-SAEs
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Application Site Tolerability Assessment Score During Treatment Period
Endpoint domain: Adverse events/effects
Primary endpoint: Mean Percent Change in PASI From Baseline to Week 8
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Binary restenosis at one year
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Sum of pain intensity differences over 24 hours (SPID24)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prediction model accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients achieving and remaining in remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to recurrence of HSV-2 lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lesion rate in HSV-2 disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety and tolerability of GW823296
Endpoint domain: Adverse events/effects
Primary endpoint: Patient enrollment
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Serum parameters of mineral metabolism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Clearances of protein-bound toxins
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes from baseline Free-fatty mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes from baseline Corporal Water
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes from baseline in the number of steps per day
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in maternal biomarkers during pregnancy up to 28 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neonatal birth weight/height
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in maternal biomarkers in pregnancy in the third trimester
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Probability of Surviving Progression-free for at Least 6 Months
Endpoint domain: Mortality/survival
Primary endpoint: Ki67 changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Maximal lingual strength (MMT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximal lingual strength (QMT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in shoulder force
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Adverse reactions associated with vaccine
Endpoint domain: Adverse events/effects
Primary endpoint: number of interventions accepted
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Ovulatory function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in DSM-IV CAPS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acute postsurgical pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of eyelid disorders
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum tolerated dose (MTD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Percent Agreement Between Acetic Acid Chromoendoscopy and Endoscopic Biopsy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Completeness of polyp resection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Polyp recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Proportion of patients achieving a favorable modified Rankin scale score (mRS 0-2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: KDIGO rise in serum creatinine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Renal Function Assessed by Calculated Glomerular Filtration Rate (cGFR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Rate of late sequelae
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in eosinophil infiltration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in eosinophil degranulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in glycemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in glycosilated Hemoglobin (Hb1Ac)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Homeostatic Model Assessment for Insulin Resistance (HOMA-IR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in FACE-Q score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Gastric Antral Volumes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Antibody Concentrations Against Vaccine Pneumococcal Serotypes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Asthma Control Test (ACT) Total Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Antibody levels against the EBOV glycoprotein GP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Resolution of pleural disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Elements of the immune response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Campbell Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Freedom from MAE
Endpoint domain: Mortality/survival
Primary endpoint: Change in frequency of CD8 T-lymphocyte precursors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: remission rate of diabetes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: number of enteric neurons per ganglia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Incidence of herbal nephropathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Proviral HIV-DNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Proportion of time with ICP ≤ 20 mmHg
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Age of puberty
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pressure-Pain Threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical and radiographic examination results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient assessment questionnaire results
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status